&w=3840&q=100)
US FDA to fast-track drug reviews for firms backing national priorities
US regulators will begin offering faster reviews to new medicines that administration officials deem as promoting the health interests of Americans, under a new initiative announced Tuesday.
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months. FDA's long-standing accelerated approval program generally issues decisions in six months for drugs that treat life-threatening diseases. Regular drug reviews take about 10 months.
Since arriving at the FDA in April, Makary has repeatedly told FDA staff they need to challenge assumptions and rethink procedures. In a medical journal commentary published last week, Makary suggested the agency could conduct rapid or instant reviews," pointing to the truncated process used to authorize the first Covid-19 vaccines under Operation Warp Speed.
For the new program, the FDA will issue a limited number of national priority vouchers to companies aligned with U.S. national priorities, the agency said in a statement. The special designation will give the selected companies access to extra FDA communications, streamlined staff reviews and the ability to submit much of their product information in advance.
Speeding up drug approvals has long been a priority of the pharmaceutical industry, which has successfully lobbied Congress to create a variety of special programs and pathways for faster reviews.
Many aspects of the plan announced Tuesday overlap with older programs. But the broad criteria for receiving a voucher will give FDA officials unprecedented discretion in deciding which companies can benefit from the fastest reviews.
"The ultimate goal is to bring more cures and meaningful treatments to the American public, Makary said in a statement.
Makary previously said the FDA should be willing to ease its scientific requirements for certain drugs, for instance, by not always requiring randomized studies in which patients are tracked over time to track safety and effectiveness. Such trials are generally considered the gold standard of medical research, though the FDA has increasingly been willing to accept smaller, less-definitive studies for rare or life-threatening diseases.
In several recent cases, the FDA has faced criticism for approving drugs based on preliminary data that didn't ultimately show benefits for patients.
The push to rapidly accelerated drug approvals is the opposite approach that Makary and his boss, Health Secretary Robert F. Kennedy Jr., have taken on vaccines.
Promising a return to gold-standard science, Kennedy previously announced that all new vaccines would have to be compared to placebo, or a dummy shot, to win approval. Kennedy and Makary also have announced a stricter policy on seasonal updates to Covid-19 shots, saying they will have to undergo new testing before they can be approved for use in healthy children and most adults.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Gazette
40 minutes ago
- India Gazette
"COVID is on a decline," says PGIMER Director Dr Vivek Lal
Chandigarh (Punjab) [India], May 18 (ANI): The Director of the Post Graduate Institute of Medical Education and Research (PGIMER), Dr Vivek Lal, has stated that COVID-19 is under control in India, with no new cases reported in the past week. He credited the strong vaccination drive led by Prime Minister Modi for keeping the virus at bay. Speaking to ANI on Tuesday, PGIMER Director Lal said, 'We are absolutely prepared for COVID-19, but it is on a decline. I don't think a single patient has tested positive in the last week. COVID-19 is under control in India because we had a very good vaccination drive under the leadership of PM Modi. The vaccination drive is still there and is protecting us.' However, despite the optimistic outlook at the national level, sporadic cases are still being reported in some regions. Rajasthan reported 29 new COVID-19 cases on Monday, taking the total number of cases this year to 456. According to the latest data, the cases were reported from various hospitals across the state, including Rajasthan Hospital, SPMC Bikaner, AIIMS Jodhpur, RTPCR Chittorgarh, SDMH Jaipur, EHCC Jaipur, SMS Jaipur, M Genix Jaipur, and RNT Jodhpur. The cases include a 20-year-old male from Banswara, an 18-year-old female from Bikaner, a 30-year-old female and a 27-year-old male from Chittorgarh, a 63-year-old female from Dausa, and a 27-year-old male from Jaipur, 14 new cases were reported, including males aged 17, 39, 53, and 40, and females aged 19, 26, 10, 75, 30, 31, 50, 29, 22, and 21. Eight cases were also reported in Jodhpur, including a 27-year-old male. Other districts reporting cases include Karauli, with a 59-year-old female, Kota, with a 27-year-old male, and Udaipur, where six cases were recorded, including males aged 48 and 45 and females aged 28, 56, 57, and 58. So far this year, Rajasthan has reported 456 COVID-19 cases, including 251 active cases, 202 recoveries, and two deaths. Jaipur continues to have the highest number of cases, with 283 reports, followed by Udaipur with 54 cases and Jodhpur with 30 cases. (ANI)
Indian Express
an hour ago
- Indian Express
Aruna Irani reveals she battled breast cancer twice, opens up about keeping it private: ‘Everything doubles'
Aruna Irani recently revealed that she battled breast cancer twice and chose to keep the news private. Stating that she was first diagnosed in 2015, the veteran actor said that she decided on medications and avoided chemotherapy before a resurgence in 2020. 'Yes. Not once but twice. Everything doubles,' she remarked. The 78-year-old recalled how she sensed something was amiss while at a shoot. 'Aise hi ek din shooting kar rahi thi, pata nahi mujhe kaise pata laga par maine bola 'Mujhe kuch lag raha hai' (One day, I was shooting as usual. I don't know how, but I just felt something and said, 'I feel like something's wrong'),' she said on the Lehren Retro podcast. While told that the lump was minor, she insisted on its removal and was operated upon. 'But I was at a shoot on the fourth day. Nothing happened. I was also hale and hearty. The doctor told me that I have to undergo chemotherapy clinically. Chemotherapy wasn't that advanced back then. So your skin turned black, and you would experience hair loss. I asked the doctor for another way, and he told me to take medicine daily. That went on for five years,' added Aruna, admitting that it was a mistake she realised after the cancer resurfaced in 2020. She also spoke about getting regular checkups done every six to eight months. 'That's how a lump was detected in 2020. It happened in the same spot on the breast. That time I got operated on. Meri hi wajah se…as pehle maine chemotherapy nahi lee thi. (Because of me…I did not opt for chemotherapy the first time. There was radiation,' continued the Laadla actor who underwent chemotherapy in 2020, just before Covid-19 pandemic. Although she did experience some hair loss, it grew back. 'Still, you lose a bit of your hair, but woh jaldi aa bhi jaate hai (it grows back quickly),' she added in the interview. In addition to cancer, she was also diagnosed with diabetes at 60. At one point, doctors even told her that her kidneys had failed, though she came back stronger. Let's understand all about breast cancer and its recurrence. Breast cancer occurs when cells in the breast begin to grow abnormally and form a lump or mass. 'While no single known cause exists, certain risk factors can increase its likelihood. These include age, family history, genetics, obesity or being overweight, lack of physical activity, alcohol consumption, and hormonal changes over a lifetime,' said Dr Meghal Sanghavi, oncologist, Wockhardt Hospitals, Mumbai Central. According to Dr Sanghavi, factors such as never having conceived or never having breastfed may also slightly raise the risk, as they influence the body's long-term exposure to hormones. 'In many cases, the exact cause remains unknown, but a combination of inherited traits and lifestyle factors can play a role,' said Dr Sanghavi. While the exact cause isn't fully understood, mutations in genes like BRCA1 and BRCA2 increase the risk for women, added Dr Jyoti Mehta, MD, radiation and clinical oncologist, Onco-Life Cancer Centre, Talegaon. 'It is possible that even after successful treatment, breast cancer can sometimes return, and this is called a recurrence,' said Dr Mehta. Does breast cancer come back if it is treated with medications in the first instance? If breast cancer is diagnosed early, it can often be treated effectively with medications such as hormone therapy or targeted drugs, said Dr Sanghavi. Dr Sanghavi said these medicines work by blocking the growth of cancer cells and preventing the spread of the disease. 'In some early-stage cases, medication alone may be sufficient. However, like with any cancer, there is always a possibility of recurrence even after what seems like complete treatment. This is why regular scans and follow-up check-ups are crucial. Rigorous follow-up, typically for up to 10 years, is recommended to monitor for any signs of the cancer returning,' said Dr Sanghavi. When breast cancer does come back, it may recur locally (in the breast area or nearby tissues) or spread to distant parts of the body, such as the bones, liver, lungs, or brain, elucidated 'Modern cancer treatments aim to minimize the risk of such recurrences as much as possible,' said Dr Vani Parmar, HOD, breast oncosurgery and surgical oncologist, KIMS Hospitals, Thane. Is chemotherapy always necessary? Dr Mehta noted that some early-stage cancers may be treated with surgery, hormone therapy, or radiation only and may not need chemotherapy. 'The expert will design the line of treatment per the woman's stage and location of the cancer,' said Dr Mehta. According to Dr Sanghavi, chemotherapy depends on the type, size, stage of cancer, and how quickly it grows. 'If the cancer is fast-growing or widespread beyond the breast, chemotherapy will be recommended. But if it is slow-growing and small, surgery or hormone therapy can be more appealing options,' said Dr Sanghavi. For example, postmenopausal women with very small, low-grade, hormone receptor-positive tumors may be effectively treated with surgery and hormone therapy without needing chemotherapy. Dr Parmar shared that chemotherapy is usually advised for younger women with triple-negative breast cancers or HER2-positive cancers because of their more aggressive nature. 'In cases where cancer has spread to lymph nodes, chemotherapy is often recommended, although the decision also depends on how many nodes are involved and other individual factors,' said Dr Parmar. Every breast cancer diagnosis is individual, and so is treatment. The key is to remain informed, follow treatments to the letter, and keep up with current screening and follow-up visits. With timely treatment and follow-up, many stay healthy and productive despite breast cancer. DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
Economic Times
2 hours ago
- Economic Times
Heart health alert: Daily cannabis use may double risk of deadly cardiac events
A recent study published in the Journal of the American Heart Association reveals that daily cannabis use nearly doubles the risk of fatal heart events. Analyzing data from over 430,000 adults, the research indicates a 25% increased risk of cardiovascular disease among daily users. Experts emphasize the need for public awareness and further research into cannabis's cardiovascular effects. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A comprehensive new study has found that daily cannabis use may nearly double the risk of dying from heart-related causes, raising significant concerns about the cardiovascular effects of marijuana as its use becomes more widespread. The research, published on June 17, 2025, in the Journal of the American Heart Association , analyzed health data spanning nearly two decades from over 430,000 American study revealed that individuals who use cannabis daily face a 25% increased risk of developing cardiovascular disease and are almost twice as likely to suffer fatal heart events compared to non-users. In contrast, occasional cannabis users did not show a significant increase in heart-related risks. These findings emerged from data collected between 1999 and 2018 through the National Health Interview Survey, making it one of the largest studies to examine the long-term cardiovascular effects of marijuana author Dr. Abra Jeffers from Massachusetts General Hospital emphasized the public health implications, stating, 'Our findings suggest that daily cannabis use may have serious cardiovascular consequences. As marijuana becomes more accessible, it's crucial that both the public and healthcare providers are aware of these potential risks.' The study underscores the need for increased awareness, especially as legalization expands and perceptions of cannabis as harmless the exact biological mechanisms remain unclear, previous research indicates that cannabis can elevate heart rate, increase blood pressure, and cause inflammation in blood vessels—all factors that may contribute to cardiovascular disease. Dr. Jeffers cautioned that these physiological effects could explain the heightened risk observed among daily from the American Heart Association have long warned about potential heart risks associated with cannabis, including arrhythmias, heart attacks, and strokes. Dr. Robert Page, a spokesperson for the association, remarked, 'This study is a wake-up call. We need more education and research to understand the full impact of cannabis on cardiovascular health.'As cannabis use grows globally, this landmark study highlights the urgent need for public health messaging and further investigation into how marijuana affects heart health, particularly for those with pre-existing cardiovascular conditions or risk factors.
